Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

"Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression" was the awarded work.

The study, which provides guidelines for the clinical management of these patients, reveals that only children with a recent stem cell transplant or with other additional diseases have a higher risk of complications from COVID-19.

This project will make societies aware of their rights related to sexual and reproductive health and empower young people to make informed and appropriate choices.

Dr. Miravitlles’ career was recognized during the 57th edition of the SEPAR National Congress held in Valencia.

The team will investigate, in animal models, the benefits of histotripsy, a technique that allows tumors to be destroyed without incision or heat, and hopes to minimize the risks and enhance the efficacy of immunotherapy.

The study also linked improved microbiota diversity to better liver function.

Més de 500 persones animades per veïns i veïnes del barri han participat en la cursa ha estat el primer dels esdeveniments que s’han organitzat per celebrar els 30 anys del Vall d’Hebron Institut de Recerca

These results reinforce the need for more individualized attention to address educational needs from an early stage.

This new technology will be completely harmless for patients, as it does not use radiation, and will offer superior image quality and better monitoring of tumours, among other benefits.

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.

VHIR organises the first meeting between entrepreneurs and the investment ecosystem.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.

For two days, communication professionals from health and research institutions, experts in the field of health communication and specialized journalists from around the world will meet to debate the key issues of the present and the future.

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.